Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.
JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...
The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...
Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
Hosted on MSN5d
Biotech Market Forecast: Top Trends for Biotech in 2025The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...
Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback